{
    "id": 24672,
    "fullName": "MYC T58A",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MYC T58A does not lie within any known functional domains of the Myc protein (UniProt.org). T58A results in enhanced Myc transforming ability in cell culture (PMID: 10825194) and is tumorigenic in animal models (PMID: 21266350).",
            "references": [
                {
                    "id": 6359,
                    "pubMedId": 10825194,
                    "title": "The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10825194"
                },
                {
                    "id": 6358,
                    "pubMedId": 21266350,
                    "title": "Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21266350"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4609,
        "geneSymbol": "MYC",
        "terms": [
            "MYC",
            "bHLHe39",
            "c-Myc",
            "MRTL",
            "MYCC"
        ]
    },
    "variant": "T58A",
    "createDate": "07/21/2016",
    "updateDate": "07/21/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8120,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Odomzo (sonidegib) inhibited survival of tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing Myc T58A in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26163,
                "profileName": "MYC T58A PTCH1 inact mut"
            },
            "therapy": {
                "id": 1428,
                "therapyName": "Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9846,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung cancer mouse cells expressing MYC T58A and loss of RB1 and TP53 demonstrated sensitivity to Alisertib (MLN8237) in culture, resulting in inhibition of cell growth (PMID: 28089889).",
            "molecularProfile": {
                "id": 27138,
                "profileName": "MYC T58A RB1 loss TP53 loss"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9856,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alisertib (MLN8237) enhanced the sensitivity of Platinol (cisplatin) combined with Vepesid (etoposide) in small cell lung cancer mouse models expressing MYC T58A and loss of TP53 and RB1, resulting in complete tumor growth inhibition, stable disease in 62.5% (10/16), and decreased tumor volume by 30% in three of the mice (PMID: 28089889).",
            "molecularProfile": {
                "id": 27138,
                "profileName": "MYC T58A RB1 loss TP53 loss"
            },
            "therapy": {
                "id": 5257,
                "therapyName": "Alisertib + Cisplatin + Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9857,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung cancer mouse cells expressing MYC T58A and loss of RB1 and TP53 demonstrated sensitivity to Barasertib (AZD1152) in culture, resulting in inhibition of cell growth (PMID: 28089889).",
            "molecularProfile": {
                "id": 27138,
                "profileName": "MYC T58A RB1 loss TP53 loss"
            },
            "therapy": {
                "id": 662,
                "therapyName": "Barasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10021,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MYC T58A in a lung cancer cell line harboring FGFR1 amplification reduced sensitivity to AZD4547 in culture and in xenograft models (PMID: 27401245).",
            "molecularProfile": {
                "id": 27225,
                "profileName": "FGFR1 amp MYC T58A"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7899,
                    "pubMedId": 27401245,
                    "title": "c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401245"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10023,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MYC T58A in a lung cancer cell line harboring FGFR1 amplification reduced sensitivity to BGJ398 in culture (PMID: 27401245).",
            "molecularProfile": {
                "id": 27225,
                "profileName": "FGFR1 amp MYC T58A"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7899,
                    "pubMedId": 27401245,
                    "title": "c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401245"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10022,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MYC T58A in a breast cancer cell line harboring FGFR2 amplification reduced sensitivity to AZD4547 in culture (PMID: 27401245).",
            "molecularProfile": {
                "id": 27226,
                "profileName": "FGFR2 amp MYC T58A"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7899,
                    "pubMedId": 27401245,
                    "title": "c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401245"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25420,
            "profileName": "MYC T58A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26163,
            "profileName": "MYC T58A PTCH1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27138,
            "profileName": "MYC T58A RB1 loss TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27225,
            "profileName": "FGFR1 amp MYC T58A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27226,
            "profileName": "FGFR2 amp MYC T58A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}